|  | |
|  | |
| Clinical data | |
|---|---|
| Trade names | Brovana | 
| Other names | Arformoterol tartrate (USAN US) | 
| AHFS/Drugs.com | Monograph | 
| MedlinePlus | a602023 | 
| License data | 
 | 
| Routes of administration | Inhalation | 
| ATC code | 
 | 
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Protein binding | 52–65% | 
| Elimination half-life | 26 hours | 
| Identifiers | |
| 
 | |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C19H24N2O4 | 
| Molar mass | 344.411 g·mol−1 | 
| 
 | |
|   (what is this?)  (verify) | |
Arformoterol, sold under the brand name Brovana among others, is a medication used for the treatment of chronic obstructive pulmonary disease (COPD).[1][2]
It is a long-acting β2 adrenoreceptor agonist (LABA) and it is the active (R,R)-(−)-enantiomer of formoterol.[1] It was approved for medical use in the United States in October 2006.[1] It is available as a generic medication.[3]
Medical uses
Arformoterol is indicated for the maintenance treatment of bronchoconstriction in people with chronic obstructive pulmonary disease (COPD).[1]
References
- 1 2 3 4 5 "Brovana- arformoterol tartrate solution". DailyMed. 13 May 2021. Retrieved 4 March 2022.
- ↑ Loh CH, Donohue JF, Ohar JA (March 2015). "Review of drug safety and efficacy of arformoterol in chronic obstructive pulmonary disease". Expert Opinion on Drug Safety. 14 (3): 463–72. doi:10.1517/14740338.2015.998196. PMID 25563342. S2CID 7767810.
- ↑ "Competitive Generic Therapy Approvals". U.S. Food and Drug Administration (FDA). 29 June 2023. Archived from the original on 29 June 2023. Retrieved 29 June 2023.
External links
- "Arformoterol". Drug Information Portal. U.S. National Library of Medicine.
- "Arformoterol tartrate". Drug Information Portal. U.S. National Library of Medicine.
    This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.